BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 - biology beyond LDL control. Nat Rev Endocrinol 2018;15:52-62. [PMID: 30367179 DOI: 10.1038/s41574-018-0110-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Momtazi-Borojeni AA, Banach M, Ruscica M, Sahebkar A. The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition. Expert Rev Clin Pharmacol 2022;:1-10. [PMID: 36193738 DOI: 10.1080/17512433.2022.2132229] [Reference Citation Analysis]
2 Kunimura A, Miura K, Segawa H, Torii S, Kondo K, Hisamatsu T, Kadota A, Fujiyoshi A, Yano Y, Nakagawa Y, Okamura T, Ueshima H; SESSA research group. Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men. J Atheroscler Thromb 2022. [PMID: 36123046 DOI: 10.5551/jat.63549] [Reference Citation Analysis]
3 Ye P, Jiang X, Qian W, Zhang J. Inhibition of PCSK9 improves the development of pulmonary arterial hypertension via down-regulating Notch3 expression.. [DOI: 10.21203/rs.3.rs-1965292/v1] [Reference Citation Analysis]
4 Muscoli S, Ifrim M, Russo M, Candido F, Sanseviero A, Milite M, Di Luozzo M, Marchei M, Sangiorgi GM. Current Options and Future Perspectives in the Treatment of Dyslipidemia. J Clin Med 2022;11:4716. [PMID: 36012957 DOI: 10.3390/jcm11164716] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Bouzoni E, Perakakis N, Connelly MA, Angelidi AM, Pilitsi E, Farr O, Stefanakis K, Mantzoros CS. PCSK9 and ANGPTL3 levels correlate with hyperlipidemia in HIV-lipoatrophy, are regulated by fasting and are not affected by leptin administered in physiologic or pharmacologic doses. Metabolism 2022;134:155265. [PMID: 35820631 DOI: 10.1016/j.metabol.2022.155265] [Reference Citation Analysis]
6 Wang F, Li M, Zhang A, Li H, Jiang C, Guo J, Wang F. PCSK9 Modulates Macrophage Polarization-Mediated Ventricular Remodeling after Myocardial Infarction. Journal of Immunology Research 2022;2022:1-18. [DOI: 10.1155/2022/7685796] [Reference Citation Analysis]
7 Efremov Y, Ermolaeva A, Vladimirov G, Gordleeva S, Svistunov A, Zaikin A, Timashev P. A mathematical model of in vitro hepatocellular cholesterol and lipoprotein metabolism for hyperlipidemia therapy. PLoS ONE 2022;17:e0264903. [DOI: 10.1371/journal.pone.0264903] [Reference Citation Analysis]
8 Soffer D, Stoekenbroek R, Plakogiannis R. Small interfering ribonucleic acid for cholesterol lowering – Inclisiran. Journal of Clinical Lipidology 2022. [DOI: 10.1016/j.jacl.2022.06.009] [Reference Citation Analysis]
9 Sun H, Meng W, Zhu J, Wang L. Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition. Naunyn Schmiedebergs Arch Pharmacol 2022;395:643-58. [PMID: 35307759 DOI: 10.1007/s00210-022-02200-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ben-naim L, Khalaila I, Papo N. Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C). Protein Engineering, Design and Selection 2022;35. [DOI: 10.1093/protein/gzab032] [Reference Citation Analysis]
11 Hu J, Zhang M, Gui L, Wan Q, Zhong J, Bai L, He M. PCSK9 Suppresses M2-Like Tumor-Associated Macrophage Polarization by Regulating the Secretion of OX40L from Hepatocellular Carcinoma Cells. Immunol Invest 2022;:1-16. [PMID: 35078374 DOI: 10.1080/08820139.2022.2027439] [Reference Citation Analysis]
12 Wang Q, Zheng B, Chen P, Lei Y. Leptin and PCSK9 concentrations are associated with vascular endothelial cytokines in patients with stable coronary heart disease. Open Medicine 2021;17:185-90. [DOI: 10.1515/med-2021-0400] [Reference Citation Analysis]
13 Kallend D, Stoekenbroek R, He Y, Smith PF, Wijngaard P. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. Journal of Clinical Lipidology 2022. [DOI: 10.1016/j.jacl.2022.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
14 Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M. A Comprehensive Review of PCSK9 Inhibitors. J Cardiovasc Pharmacol Ther 2022;27:10742484221100107. [PMID: 35593194 DOI: 10.1177/10742484221100107] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Sundararaman SS, Peters LJF, Nazir S, Marquez AB, Bouma JE, Bayasgalan S, Döring Y, van der Vorst EPC. PCSK9 Imperceptibly Affects Chemokine Receptor Expression In Vitro and In Vivo. Int J Mol Sci 2021;22:13026. [PMID: 34884827 DOI: 10.3390/ijms222313026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kosmas CE, Pantou D, Sourlas A, Papakonstantinou EJ, Echavarria Uceta R, Guzman E. New and emerging lipid-modifying drugs to lower LDL cholesterol. Drugs Context 2021;10:2021-8-3. [PMID: 34795777 DOI: 10.7573/dic.2021-8-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
17 Xia XD, Peng ZS, Gu HM, Wang M, Wang GQ, Zhang DW. Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications. Front Cardiovasc Med 2021;8:764038. [PMID: 34782856 DOI: 10.3389/fcvm.2021.764038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
18 Xie B, Shi X, Li Y, Xia B, Zhou J, Du M, Xing X, Bai L, Liu E, Alvarez F, Jin L, Deng S, Mitchell GA, Pan D, Li M, Wu J. Deficiency of ASGR1 in pigs recapitulates reduced risk factor for cardiovascular disease in humans. PLoS Genet 2021;17:e1009891. [PMID: 34762653 DOI: 10.1371/journal.pgen.1009891] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Liu L, Sheng C, Lyu Z, Dai H, Chen K. Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study. Front Nutr 2021;8:755834. [PMID: 34712689 DOI: 10.3389/fnut.2021.755834] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Roudaut M, Idriss S, Caillaud A, Girardeau A, Rimbert A, Champon B, David A, Lévêque A, Arnaud L, Pichelin M, Prieur X, Prat A, Seidah NG, Zibara K, Le May C, Cariou B, Si-Tayeb K. PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs. Stem Cell Reports 2021:S2213-6711(21)00539-7. [PMID: 34739847 DOI: 10.1016/j.stemcr.2021.10.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Barisione C, Verzola D, Garibaldi S, Ferrari PF, Garibotto G, Ameri P, Pane B, Spinella G, Pratesi G, Palombo D. Renal Ischemia/Reperfusion Early Induces Myostatin and PCSK9 Expression in Rat Kidneys and HK-2 Cells. Int J Mol Sci 2021;22:9884. [PMID: 34576046 DOI: 10.3390/ijms22189884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 He Y, Rodrigues RM, Wang X, Seo W, Ma J, Hwang S, Fu Y, Trojnár E, Mátyás C, Zhao S, Ren R, Feng D, Pacher P, Kunos G, Gao B. Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. J Clin Invest 2021;131:141513. [PMID: 33301423 DOI: 10.1172/JCI141513] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 30.0] [Reference Citation Analysis]
23 Chemello K, Jaafar AK, Lambert G. Heart to heart with PCSK9. Eur Heart J 2021:ehab480. [PMID: 34324660 DOI: 10.1093/eurheartj/ehab480] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 François M, Thédrez A, Garçon D, Ayer A, Sotin T, Dijk W, Blanchard C, Chadeuf G, Arnaud L, Croyal M, Van Landeghem L, Touvron M, Prieur X, Roubtsova A, Seidah N, Prat A, Cariou B, Le May C. PCSK9 is not secreted from mature differentiated intestinal cells. J Lipid Res 2021;:100096. [PMID: 34280453 DOI: 10.1016/j.jlr.2021.100096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Sundararaman SS, Döring Y, van der Vorst EPC. PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. Biomedicines 2021;9:793. [PMID: 34356856 DOI: 10.3390/biomedicines9070793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
26 Miname MH, Rocha VZ, Santos RD. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently? Curr Atheroscler Rep 2021;23:40. [PMID: 34146170 DOI: 10.1007/s11883-021-00936-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
27 Kim E, Kim YM, Ahn J, Chae HS, Chin YW, Kim J. Prenylated Flavonoid Glycosides with PCSK9 mRNA Expression Inhibitory Activity from the Aerial Parts of Epimedium koreanum. Molecules 2021;26:3590. [PMID: 34208231 DOI: 10.3390/molecules26123590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Maligłówka M, Bułdak Ł, Okopień B, Bołdys A. The consequences of PCSK9 inhibition in selected tissues. Postepy Hig Med Dosw 2021;75:385-97. [DOI: 10.5604/01.3001.0014.9127] [Reference Citation Analysis]
29 Wang P, Zhang W, Feng Z, Zhang J, Sun Y, Zhang W. LDL‑induced NLRC3 inflammasome activation in cardiac fibroblasts contributes to cardiomyocytic dysfunction. Mol Med Rep 2021;24:526. [PMID: 34036387 DOI: 10.3892/mmr.2021.12165] [Reference Citation Analysis]
30 Zeitlinger M, Bauer M, Reindl-Schwaighofer R, Stoekenbroek RM, Lambert G, Berger-Sieczkowski E, Lagler H, Oesterreicher Z, Wulkersdorfer B, Lührs P, Galabova G, Schwenke C, Mader RM, Medori R, Landlinger C, Kutzelnigg A, Staffler G. A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. Eur J Clin Pharmacol 2021. [PMID: 33969434 DOI: 10.1007/s00228-021-03149-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
31 Gormley M, Yarmolinsky J, Dudding T, Burrows K, Martin RM, Thomas S, Tyrrell J, Brennan P, Pring M, Boccia S, Olshan AF, Diergaarde B, Hung RJ, Liu G, Legge D, Tajara EH, Severino P, Lacko M, Ness AR, Davey Smith G, Vincent EE, Richmond RC. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study. PLoS Genet 2021;17:e1009525. [PMID: 33886544 DOI: 10.1371/journal.pgen.1009525] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
32 Hu D, Guo Y, Wu R, Shao T, Long J, Yu B, Wang H, Luo Y, Lu H, Zhang J, Chen YE, Peng D. New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation. ATVB 2021;41. [DOI: 10.1161/atvbaha.120.315708] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
33 Aguilar-Ballester M, Hurtado-Genovés G, Taberner-Cortés A, Herrero-Cervera A, Martínez-Hervás S, González-Navarro H. Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. Int J Mol Sci 2021;22:E660. [PMID: 33440821 DOI: 10.3390/ijms22020660] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
34 Xu B, Li S, Fang Y, Zou Y, Song D, Zhang S, Cai Y. Proprotein Convertase Subtilisin/Kexin Type 9 Promotes Gastric Cancer Metastasis and Suppresses Apoptosis by Facilitating MAPK Signaling Pathway Through HSP70 Up-Regulation. Front Oncol 2020;10:609663. [PMID: 33489919 DOI: 10.3389/fonc.2020.609663] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
35 Hu D, Mao L, Tang X, Chen J, Guo X, Luo Q, Kuang J, Zhang T, Liu R, Yuan S, Yu B, Peng D. Nuclear magnetic resonance reveals postprandial low-density lipoprotein cholesterol determined by enzymatic method could be a misleading indicator. Clin Chim Acta 2021;514:59-65. [PMID: 33333042 DOI: 10.1016/j.cca.2020.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Abdul NS, Chuturgoon AA. Fumonisin B1 regulates LDL receptor and ABCA1 expression in an LXR dependent mechanism in liver (HepG2) cells. Toxicon 2021;190:58-64. [PMID: 33338448 DOI: 10.1016/j.toxicon.2020.12.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
37 Claessen BE, Guedeney P, Gibson CM, Angiolillo DJ, Cao D, Lepor N, Mehran R. Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. J Am Heart Assoc 2020;9:e018897. [PMID: 33289416 DOI: 10.1161/JAHA.120.018897] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
38 Sattari R, Palizban A, Khanahmad H. Single-Strand DNA-Like Oligonucleotide Aptamer Against Proprotein Convertase Subtilisin/Kexin 9 Using CE-SELEX: PCSK9 Targeting Selection. Cardiovasc Drugs Ther 2020;34:475-85. [PMID: 32415571 DOI: 10.1007/s10557-020-06986-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
39 Revilla G, Cedó L, Tondo M, Moral A, Pérez JI, Corcoy R, Lerma E, Fuste V, Reddy ST, Blanco-Vaca F, Mato E, Escolà-Gil JC. LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. Semin Cancer Biol 2021;73:134-57. [PMID: 33249202 DOI: 10.1016/j.semcancer.2020.11.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
40 Zeller M, Lambert G, Farnier M, Maza M, Nativel B, Rochette L, Vergely C, Cottin Y. PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction. Nutr Metab Cardiovasc Dis 2021;31:880-5. [PMID: 33546945 DOI: 10.1016/j.numecd.2020.11.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
41 Andreadou I, Tsoumani M, Vilahur G, Ikonomidis I, Badimon L, Varga ZV, Ferdinandy P, Schulz R. PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation. Front Physiol 2020;11:602497. [PMID: 33262707 DOI: 10.3389/fphys.2020.602497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
42 Choi IJ, Lim S, Lee D, Lee WJ, Lee KY, Kim MJ, Jeon DS. Relation of Proprotein Convertase Subtilisin/Kexin Type 9 to Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention. Am J Cardiol 2020;133:54-60. [PMID: 32798044 DOI: 10.1016/j.amjcard.2020.07.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Rakipovski G, Hovingh GK, Nyberg M. Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin? Current Opinion in Lipidology 2020;31:340-6. [DOI: 10.1097/mol.0000000000000718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Duprez DA, Handelsman Y, Koren M. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. Vasc Health Risk Manag 2020;16:403-18. [PMID: 33116551 DOI: 10.2147/VHRM.S261719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Handhle A, Viljoen A, Ramachandran R, Wierzbicki AS. Low cholesterol syndrome and drug development. Curr Opin Cardiol 2020;35:423-7. [PMID: 32452920 DOI: 10.1097/HCO.0000000000000745] [Reference Citation Analysis]
46 Yu Y, Su X, Qin Q, Hou Y, Zhang X, Zhang H, Jia M, Chen Y. Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases. Pharmacological Research 2020;159:105009. [DOI: 10.1016/j.phrs.2020.105009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
47 Kuo W, Stevens JM, Ersig AL, Johnson HM, Tung T, Bratzke LC. Does 24-h Activity Cycle Influence Plasma PCSK9 Concentration? A Systematic Review and Meta-Analysis. Curr Atheroscler Rep 2020;22. [DOI: 10.1007/s11883-020-00843-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Capoulade R, Cariou B. Editorial commentary: Lp(a) and calcific aortic valve stenosis: Direct LPA targeting or PCSK9-Lowering therapy? Trends Cardiovasc Med 2021;31:312-4. [PMID: 32623063 DOI: 10.1016/j.tcm.2020.06.009] [Reference Citation Analysis]
49 Kim EJ, Wierzbicki AS. The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. Ther Adv Chronic Dis 2020;11:2040622320924569. [PMID: 32537117 DOI: 10.1177/2040622320924569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
50 Molina-Vega M, Castellano-Castillo D, Sánchez-Alcoholado L, Plaza-Andrade I, Perera-Martin G, Cabrera-Mulero A, Fernández-García JC, Ramos-Molina B, Cardona F, Tinahones FJ. Relationship of Zonulin with Serum PCSK9 Levels after a High Fat Load in a Population of Obese Subjects. Biomolecules 2020;10:E748. [PMID: 32403394 DOI: 10.3390/biom10050748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Zhang X, Stiekema LCA, Stroes ESG, Groen AK. Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a). Lipids Health Dis 2020;19:91. [PMID: 32393252 DOI: 10.1186/s12944-020-01280-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Pel P, Chae HS, Nhoek P, Kim YM, Khiev P, Kim GJ, Nam JW, Choi H, Choi YH, Chin YW. A stilbene dimer and flavonoids from the aerial parts of Chromolaena odorata with proprotein convertase subtilisin/kexin type 9 expression inhibitory activity. Bioorg Chem 2020;99:103869. [PMID: 32335358 DOI: 10.1016/j.bioorg.2020.103869] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
53 Boccara F, Kumar P, Caramelli B, Calmy A, López JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. Am Heart J 2020;220:203-12. [PMID: 31841795 DOI: 10.1016/j.ahj.2019.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
54 Watts GF, Gidding SS, Mata P, Pang J, Sullivan DR, Yamashita S, Raal FJ, Santos RD, Ray KK. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol 2020;17:360-77. [DOI: 10.1038/s41569-019-0325-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 24.5] [Reference Citation Analysis]
55 Ramin-mangata S, Wargny M, Pichelin M, Le May C, Thédrez A, Blanchard V, Nativel B, Santos RD, Benseñor IM, Lotufo PA, Lambert G, Cariou B. Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. Atherosclerosis 2020;293:49-56. [DOI: 10.1016/j.atherosclerosis.2019.11.027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
56 Pastori D, Ettorre E, Carnevale R, Nocella C, Bartimoccia S, Del Sordo E, Cammisotto V, Violi F, Pignatelli P, Saliola M, Casciaro MA, Farcomeni A, Rubino L, Marchese C, Santulli M, Vasaturo F, Castellani V, Menichelli D. Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort. Atherosclerosis 2019;289:195-200. [DOI: 10.1016/j.atherosclerosis.2019.07.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
57 Adorni MP, Ruscica M, Ferri N, Bernini F, Zimetti F. Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease. Front Aging Neurosci 2019;11:120. [PMID: 31178716 DOI: 10.3389/fnagi.2019.00120] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
58 Mäkelä KA, Leppäluoto J, Jokelainen J, Jämsä T, Keinänen-Kiukaanniemi S, Herzig KH. Effect of Physical Activity on Plasma PCSK9 in Subjects With High Risk for Type 2 Diabetes. Front Physiol 2019;10:456. [PMID: 31114503 DOI: 10.3389/fphys.2019.00456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]